ClinicalTrials.gg
RecruitingNCT07803029Updated Sep 3, 2026

Bioimpedance Spectroscopy (BIS): Fluid Changes in Hemodialysis Patients

An interventional study of Bioimpedance analysis in Hemodialysis, sponsored by Per Ivarsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Per Ivarsen · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled May 2025, registered Aug 2026).
  • Started May 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In connection with dialysis treatment, fluid and salt balance changes. Some kidney disease patients experience fluid accumulation in the body and need to have excess fluid removed via the dialysis machine. Others have too little fluid in their bodies and experience general symptoms. The amount of fluid that needs to be removed is an individual assessment and can be difficult to determine. Today, fluid removal is determined based on signs such as water in the lungs, swollen legs, and blood pressure. By using a so-called bioimpedance spectroscopy (BIS) device, it os possible measure how much fluid is in the body. However, the calculations that BIS devices use are developed for healthy individuals and do not work optimally during dialysis. Therefore, the investigators will use the actual measurements and compare them with fluid extraction and weight changes to examine their relationship. Hemodialysis patients with ultrafiltration on 3 consecutive dialysis days in order to investigate whether there is a difference in measurements after the long dialysis break and whether the measurements are the same when you are being drawn to your dry weight are included. Other patients without fluid removed during dialysis will be investigated once. I the study the absolute blood volume is also measured, that is, how much fluid is in the bloodstream. This is also an expression of the body's total fluid volume. By combining the various measurements, the study will gain increased knowledge about your hydration status. If the measurement methods have sufficient precision, the use of BIS and measurement of total blood volume may contribute to a more accurate determination of your dry weight.

Read the detailed description

To investigate whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients. Accuracy is low when using prediction equations that are integrated into the individual BIS device. This challenges the application in clinical practice. Furthermore, the prediction equation is not available for most devices. Small studies suggest greater accuracy when using raw data, which could make BIS measurements clinically applicable. Detailed purpose. To examine whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients.

  1. Ensure consistency in measurements of raw impedance data (Phase angle, RE, RI, R∞, and Cm) between different BIS devices (here: Fresenius BCM®, SFB7®, and SOZO® from ImpediMed).
  2. Compare intradialytic ∆RE, ∆R∞, and ∆Cm against changes in absolute blood volume, BP, weight, and fluid removal in HD patients with fluid removal.
  3. Is the phase angle consistent over the 3 dialysis days in a week for center dialysis patients with fluid retention?
  4. Compare intradialytic ∆RE, ∆R∞, and ∆Cm against changes in absolute blood volume, blood pressure, and weight in hemodialysis patients without fluid retention.
  5. Compare intradialytic ∆blood pressure, ∆weight, ∆ABV, fluid retention, and BIS measured changes (∆RE, ∆R∞, ∆Cm) for patients undergoing home hemodialysis with patients undergoing center hemodialysis.
02

Conditions studied

  • Hemodialysis

Browse trials for

Keywords

  • hemodialysis
  • bioimpedance
  • absolute blood volume
  • total body water
  • extracellular body water
  • intracellular water
  • body weight
03

In context

Body Weight

657 studies on the registry are indexed under Body Weight; 76 are open to participants now.

This study's planned enrollment of 42 is below the median of 71 across 500 interventional studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

Per Ivarsen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hemodialysis for more than 3 month Hemodynamic stabile during a dialysis session

-

Exclusion criteria

Exclusion Criteria:

  1. Amputated limbs.
  2. Pregnant.
  3. Extremity palsy and paralysis.
  4. Implanted electronic device (e.g., pacemaker or ICD).
  5. Regular use of dialysate sodium proliferation.
  6. Hip, knee and shoulder prosthesis.
  7. Dialysis fistula in both arms.
  8. Inability to give .
  9. History of discontinuation of dialysis treatment prematurely.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Active comparator
    Hemodialysis patient

    Measurement wil be donne before and after a hemodialysis. Bioimpendance spectroscopy is measured with 3 different bioimpedance apperatur. Absolute blood volumen is measured 5-10 minutes after starting and before stopping the dialysis session. For center hemodialysis patients with ultrafiltration measurement til be performed on 3 consecutive days and for patient center hemodialysis patient meaurement wil be performed once with also apply for Home hemodialysis patients.

    Device: Bioimpedance analysis

Interventions

  • DeviceBioimpedance analysis

    Comparing the perfomance of original data from 3 different bioimpedance apparatur and test there precision and accurary compared to ultrafiltration. And whether the performance of measuring absolut blood volume is better

06

What researchers measure

Primary outcomes

  1. Changes in BIS measured resistance and fluid removed

    To investigate whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients before and after a hemodialysis session of 4 hours duration. Weight loss during a hemodialysis session is equivalent to fluid removed. The meausement are don for up to oen week 1. To determine consistency in measurements of raw impedance data (Ω) between different BIS devices (here: Fresenius BCM ®, SFB7 ® and SOZO ® from Imped-iMed). 2. Change in raw impedance data (Ω) during a hemodialysis session of 4 hours 3. Degree of ultrafiltrating (ml) a hemodialysis session of 4 hours 4. Change in absolute blood volume (ml) during a hemodialysis session of 4 hours 4\) In a subset of patients test if the length of the of pause (days) between hemodialysis session influence the raw impedance measurements.

    Time frame: From enrollment to the end of the dialysis session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07803029
Lead sponsor
Per Ivarsen
Responsible party
Per Ivarsen (Clinical Professor, University of Aarhus) — Sponsor-investigator
First posted
Sep 3, 2026
Start date
May 11, 2025
Primary completion
Oct 16, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 3, 2026

Study contacts

Per Ivarsen, MD
Contact
per.ivarsen@clin.au.dk
+457845000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion